KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Emergent BioSolutions (EBS) Change in Cash: 2009-2024

Historic Change in Cash for Emergent BioSolutions (EBS) over the last 16 years, with Dec 2024 value amounting to -$6.1 million.

  • Emergent BioSolutions' Change in Cash fell 125.53% to -$21.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $92.8 million, marking a year-over-year increase of 35.28%. This contributed to the annual value of -$6.1 million for FY2024, which is 98.85% up from last year.
  • Latest data reveals that Emergent BioSolutions reported Change in Cash of -$6.1 million as of FY2024, which was up 98.85% from -$530.9 million recorded in FY2023.
  • In the past 5 years, Emergent BioSolutions' Change in Cash ranged from a high of $453.5 million in FY2020 and a low of -$530.9 million during FY2023.
  • Over the past 3 years, Emergent BioSolutions' median Change in Cash value was -$6.1 million (recorded in 2024), while the average stood at -$156.9 million.
  • In the last 5 years, Emergent BioSolutions' Change in Cash soared by 715.65% in 2020 and then tumbled by 900.75% in 2023.
  • Emergent BioSolutions' Change in Cash (Yearly) stood at $453.5 million in 2020, then plummeted by 109.97% to -$45.2 million in 2021, then surged by 246.68% to $66.3 million in 2022, then crashed by 900.75% to -$530.9 million in 2023, then soared by 98.85% to -$6.1 million in 2024.